KCNC1 and epilepsy: Although further studies are needed to reveal the relationship between Kv4.3 and preventive efficacy against migraine attacks, this subtype of Kv4 has been regarded as one of the pharmacological targets for the development of new drugs against epilepsy and neuropathic pain [59].